Eye drops containing luteolin derivative and preparation method thereof
By loading the luteolin derivative LTD2 on liposomes to form eye drops, the side effects of oral administration in the prevention and treatment of diabetic retinopathy and poor drug permeability are solved, and effective retinal drug delivery and treatment are achieved Effect.
Patent Information
- Application Number
- CN202411584299.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-07
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prevention and treatment of diabetic retinopathy, existing luteolin derivatives have a large gastrointestinal reaction through oral administration and may increase the burden on the kidneys. Its water-solubleness makes it difficult to enter the eye through the cornea, which has poor effect.
The luteolin derivative LTD2 is loaded into liposomes to form eye drops, and the bilayer structure of the liposomes is stabilized and transported to the retina through the cornea and sclera, improving the stability and permeability of the drug.
Effectively prevent and alleviate the early stage of diabetic retinopathy, avoid the adverse effects of long-term gastrointestinal administration, improve the therapeutic effect, and simplify the preparation process, and have the potential for industrial production.
Smart Images

Figure CN119074655A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical technology, and in particular to an eye drop containing a luteolin derivative and a preparation method thereof. Background Art
[0002] Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia. Long-term hyperglycemia damages large and small blood vessels and seriously endangers the heart, brain, kidneys, peripheral nerves, eyes, feet, etc., making diabetes the disease with the most complications. Diabetes mellitus vascular complications (DMVC) are the most serious complications of DM and the main cause of death and disability in diabetes. 80% of diabetic patients die from this complication. DMVC mainly includes large vessel complications (coronary heart disease, cerebral stroke and atherosclerosis, etc.) and microvascular complications (diabetic nephropathy, retinopathy, diabetic foot and peripheral neuropathy, etc.). The exact pathogenesis of DMVC is not completely clear. Hyperglycemia is the primary driving force for vascular disease, which is mainly related to the induction of vascular damage (VD) by a variety of comprehensive factors such as glucose metabolism, lipid metabolism disorders and hypertension in diabetes.
[0003] Luteolin (LTD) extracted from Erigeron breviscapus is a natural flavonoid compound with multiple pharmacological effects such as anti-inflammatory, antioxidant, and immune regulation. It has been proven to be used to control diabetic complications, but luteolin has poor solubility and is difficult to make into medicine. In the inventor's previous research (patent CN 110511201A), a series of luteolin derivatives were obtained by modifying luteolin. Further experiments showed that among these luteolin derivatives, 3'-(dimethylamino)ethoxy-luteolin (hereinafter referred to as LTD2) has the pharmacological effect of antagonizing diabetic vascular damage. It is not only better in efficacy than LTD, but also has significantly improved solubility, which reduces the difficulty of preparing preparations. It has great potential in the research and development of prevention and treatment of diabetic retinopathy. However, in subsequent studies, it was found that oral administration has a large gastrointestinal reaction, and diabetes is a long-term chronic disease. Long-term systemic medication may increase the burden on the kidneys and produce greater side effects, which hinders the use of LTD2 in the prevention and treatment of diabetic retinopathy. Summary of the invention
[0004] The object of the present invention is to provide an eye drop containing luteolin derivatives and a preparation method thereof, wherein the eye drop can prevent and alleviate the early stage of diabetic retinopathy by topical eye drops, is suitable for patients with long-term diabetes but no retinopathy, and can prevent the occurrence and progression of diabetic retinopathy.
[0005] The embodiment of the present invention is achieved as follows: An eye drop containing a luteolin derivative, the eye drop comprising liposomes and the luteolin derivative loaded on the liposomes; Among them, the structural formula of luteolin derivatives is .
[0006] The beneficial effects of the embodiments of the present invention are: The embodiment of the present invention provides an eye drop containing a luteolin derivative and a preparation method thereof, wherein the luteolin derivative LTD2 is prepared in the form of eye drops to avoid the adverse effects of long-term enteral administration. Since LTD2 is more water-soluble than LTD, it has obvious advantages in being prepared into a preparation. However, due to its high water solubility, LTD2 is not easy to enter the eye through the cornea and sclera composed of a lipid bilayer cell structure. Loading it on liposomes not only improves the stability of the drug molecules, but also facilitates the drug to penetrate directly into the retina, which can effectively prevent and alleviate early diabetic retinopathy. In addition, the preparation method of the eye drops is simple and has the potential to achieve large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0008] Figure 1 A schematic diagram of a mouse retinal flat mount provided in a test example of the present invention; Figure 2 This is the mouse retina OCT test result provided by the test example of the present invention. DETAILED DESCRIPTION
[0009] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0010] The eye drops containing luteolin derivatives and the preparation method thereof according to the embodiments of the present invention are described in detail below.
[0011] An embodiment of the present invention provides an eye drop containing a luteolin derivative, wherein the eye drop comprises a liposome, and a luteolin derivative loaded on the liposome; Among them, the structural formula of luteolin derivatives is .
[0012] Among them, the preparation method of the luteolin derivative LTD2 is carried out with reference to CN 110511201A, which will not be repeated here. In the early research of the inventor, the luteolin derivative LTD2 was confirmed to be used for the prevention and treatment of diabetic retinopathy through oral administration, but oral administration has a large gastrointestinal reaction, and diabetes is a long-term chronic disease. Long-term systemic medication may increase the burden on the kidneys and produce significant side effects, which hinders the use of LTD2 in the prevention and treatment of diabetic retinopathy.
[0013] After a large number of experiments, the inventors further discovered that using LTD2 in eye drops can also exert its efficacy, and this local treatment method is highly targeted, requires less medication, and can achieve better therapeutic effects. Moreover, LTD2 has a much higher water solubility than LTD, which makes it easier to dissolve in the process of preparing eye drops, and has obvious advantages. However, during use, the inventors further discovered that it is precisely because of the high water solubility of LTD2 that it is not easy to enter the eye through the cornea and sclera composed of lipid bilayer cell structures, and the therapeutic effect is far from what expected.
[0014] To address this issue, the inventors introduced liposomes into LTD2 eye drops. Liposomes are closed vesicles with a bilayer structure. The inside of the vesicle is a hydrophilic end, which can stabilize LTD2 therein, while the phospholipid molecule layer outside the vesicle can pass through the cornea and sclera and transport LTD2 to the vitreous body and retina, thereby better exerting the therapeutic effect of LTD2.
[0015] Furthermore, in the eye drops, the concentration of the luteolin derivative is 0.01wt% to 0.05wt%. Within the above concentration range, the therapeutic effect is better and no eye discomfort is caused.
[0016] Optionally, the drug loading of the liposome is 10wt%~30wt%. Within the above drug loading range, the liposome has a better encapsulation effect on LTD2 and a more stable overall structure. The particle size of the liposome is 100~400 nm. Within this particle size range, the encapsulation of LTD2 is better and it also has better permeability.
[0017] Optionally, the liposomes used in the present invention are neutral liposomes. Neutral liposomes have better stability and biocompatibility, can better act on the eyeball, and avoid eye discomfort.
[0018] The embodiment of the present invention further provides a method for preparing the eye drops containing the luteolin derivatives, which comprises: S1. dissolving lecithin and cholesterol in an organic solvent to obtain an organic phase solution; S2. evaporating the organic phase solution to remove the solvent to obtain a lipid film; S3. mixing the lipid film with an aqueous solution containing a luteolin derivative to obtain a suspension; S4. Dilute the suspension with sodium chloride solution and adjust its osmotic pressure to obtain eye drops.
[0019] Furthermore, the osmotic pressure of the eye drops is within the above range, which is not only conducive to the penetration of liposomes, but also does not cause eye discomfort.
[0020] Optionally, in step S1, the organic solvent may be methanol, ethanol, etc., which are easily volatilized and removed and have little irritation to the human body.
[0021] Optionally, the lipid film and the aqueous solution are mixed under ultrasonic conditions with stirring, the ultrasonic frequency being 20-50 Hz, the ultrasonic time being 15-30 min, and the stirring speed being 500-1000 rpm. Under such conditions, the liposomes are helped to reach the desired particle size requirements, and the particle size distribution is more uniform.
[0022] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0023] Example 1 This embodiment provides an eye drop containing a luteolin derivative, the eye drop comprising liposomes and a luteolin derivative LTD2 loaded on the liposomes, wherein the concentration of LTD2 is 0.02wt%, and the drug loading amount of the liposomes is 20wt%.
[0024] The preparation method thereof comprises: S1. dissolving lecithin and cholesterol in ethanol to obtain an organic phase solution; S2. evaporating the organic phase solution to remove the solvent to obtain a lipid film; S3. stirring the lipid film and the aqueous solution containing the luteolin derivative at an ultrasonic frequency of 40 Hz and a stirring speed of 800 rpm for 20 min to obtain a suspension; S4. The suspension is diluted with a sodium chloride solution and its osmotic pressure is adjusted to 296 mOsmol / kg to obtain the eye drops.
[0025] Example 2 This embodiment provides an eye drop containing a luteolin derivative, the eye drop comprising liposomes and a luteolin derivative LTD2 loaded on the liposomes, wherein the concentration of LTD2 is 0.05wt%, and the drug loading amount of the liposomes is 30wt%.
[0026] The preparation method thereof comprises: S1. dissolving lecithin and cholesterol in ethanol to obtain an organic phase solution; S2. evaporating the organic phase solution to remove the solvent to obtain a lipid film; S3. stirring the lipid film and the aqueous solution containing the luteolin derivative at an ultrasonic frequency of 50 Hz and a stirring speed of 500 rpm for 30 min to obtain a suspension; S4. The suspension is diluted with a sodium chloride solution and its osmotic pressure is adjusted to 300 mOsmol / kg to obtain the eye drops.
[0027] Example 3 This embodiment provides an eye drop containing a luteolin derivative, the eye drop comprising liposomes and a luteolin derivative LTD2 loaded on the liposomes, wherein the concentration of LTD2 is 0.01wt%, and the drug loading amount of the liposomes is 10wt%.
[0028] The preparation method thereof comprises: S1. dissolving lecithin and cholesterol in ethanol to obtain an organic phase solution; S2. evaporating the organic phase solution to remove the solvent to obtain a lipid film; S3. stirring the lipid film and the aqueous solution containing the luteolin derivative at an ultrasonic frequency of 20 Hz and a stirring speed of 1000 rpm for 30 min to obtain a suspension; S4. The suspension is diluted with a sodium chloride solution and its osmotic pressure is adjusted to 292 mOsmol / kg to obtain the eye drops.
[0029] Comparative Example 1 This comparative example provides an eye drop containing a luteolin derivative, which is prepared by directly dissolving LTD2 in a sodium chloride aqueous solution to form a 0.02 wt % solution, and adjusting the osmotic pressure to 296 mOsmol / kg.
[0030] Comparative Example 2 This comparative example provides an eye drop containing a luteolin derivative, wherein LTD2 is directly dissolved in a sodium chloride aqueous solution to prepare a 0.1 wt % solution, and the osmotic pressure thereof is adjusted to 296 mOsmol / kg.
[0031] Comparative Example 3 This comparative example provides an eye drop containing luteolin, which directly dissolves luteolin LTD in a sodium chloride aqueous solution to prepare a 0.02wt% solution. However, due to the poor solubility of LTD, the added LTD cannot be completely dissolved. Further reducing the amount of LTD added, until the concentration of 0.002wt%, it still cannot be completely dissolved.
[0032] Comparative Example 4 This comparative example provides an eye drop containing luteolin, and its preparation method is basically the same as that of Example 1, except that LTD2 is replaced with an equimolar amount of LTD. In actual operation, the addition of liposomes did not improve the solubility of LTD, and LTD still could not be completely dissolved at the target concentration. This shows that LTD is not suitable for making eye drops.
[0033] Test Example 1 This test example uses the eye drops of Examples 1 to 3 and Comparative Examples 1 to 2 for eye drop administration (DT), and uses oral administration (ST) as a control example to compare their therapeutic effects. The specific method is as follows: The DR mouse model was established by intraperitoneal injection of STZ into mice. The mouse model was divided into a 4-week early preventive administration group and a 12-week therapeutic administration group. The drug was administered by eye drops (DT) at 0.02%, three times a day; oral gavage (ST), at 200 mg / kg, once a day for 8 weeks. OCT and ERG tests were performed before and after administration. The mice were killed after 8 weeks, and the retina was removed for retinal vascular flat-mount functional examination to explore the prevention and treatment mechanism of LTD2 on diabetic retinopathy. The experimental results are shown in Table 1.
[0034] Table 1. Results of drug efficacy tests Retinal vessel density (%) Retinal thickness (μm) <![CDATA[Retinal electrophysiology ERG Oscillation 3.0 OPS 2 (uV)]]> Retinal VEGFA expression levels Normal mice 61 243 45 0.8 Model mice 43 232 21 3.5 Example 1 58 239 32 0.9 Example 2 59 242 35 1.1 Example 3 57 241 34 1.2 Comparative Example 1 49 238 28 2.3 Comparative Example 2 52 236 27 1.9 Comparison Example 56 235 33 1.2 As can be seen from Table 1, based on the test data of retinal flat mounts, the eye drops of Examples 1 to 3 of the present invention have significantly higher retinal vascular density than the model group after treatment, with a thickness of 239 to 242 μm, slightly lower than that of normal mice, and significantly higher than that of the model group. This shows that the eye drops of Examples 1 to 3 of the present invention can effectively reduce diabetes-related retinal vascular damage and inhibit retinal thinning. In addition, retinal electrophysiological ERG oscillation data are often used to characterize the degree of neuronal activity in the retina. It can be seen from the retinal electrophysiological ERG oscillation data that although the data of Examples 1 to 3 of the present invention are significantly lower than those of normal mice, they are still much higher than those of model mice. It can be seen that the eye drops of the embodiments of the present invention can alleviate the functional impairment caused by diabetes. The retinal VEGFA expression level is used to characterize the hypoxic state of the retina. The retinal VEGFA expression levels of Examples 1 to 3 of the present invention are between 0.9 and 1.1, which is basically equivalent to that of normal mice.
[0035] In contrast, in comparative example 1, without the addition of liposomes, the water solubility of LTD2 was poor and it was difficult to penetrate into the eye, resulting in poor effect. The retinal vascular density was reduced to 49%, and the retinal thickness was also thinned to 238μm, with obvious differences in effect. At the same time, its ERG oscillation was also significantly reduced, indicating that the retinal function was significantly damaged, the VEGFA expression level reached 2.3, and the retina was in a state of hypoxia to a certain extent.
[0036] Comparative Example 2 increased the concentration of LTD2 on the basis of Comparative Example 1, but the effect was not significantly improved, and even slightly worsened. The most obvious thing was that the VEGFA expression level reached 1.9. This shows that the appropriate concentration level is conducive to the efficacy of LTD2, and excessive use will lead to retinal hypoxia.
[0037] The control group was administered by oral gavage, with a dosage significantly higher than that of eye drops, but the therapeutic effect was worse, with the retinal vascular density reaching only 47%, the retinal thickness 235 μm, and the results of ERG oscillation and VEGFA expression levels far less than those of the embodiments of the present invention. In addition, the drug burden brought to the organism by large-scale administration cannot be ignored.
[0038] Figure 1 The schematic diagram of the mouse retinal flat mount is shown, and it can be seen that the blood vessel density of the model mice (M group) is significantly lower than that of the normal mice (N group), and the blood vessels are relatively dark. However, the model mice (DT group) treated with the eye drops of Example 1 are not much different from normal mice, and the blood vessels are high in density and clearly visible.
[0039] Figure 2 The results of retinal thickness detected by mouse retinal OCT were shown. The retinal thickness of the model mice (M group) decreased from 243μm to 232μm compared with that of normal mice (N group). Both eye drops (DT group) and oral administration (ST group) can effectively inhibit retinal thinning. The retinal thickness of the DT group reached 239μm, while the retinal thickness of the ST group only reached 235μm. It can be seen that the effect of eye drops administered by eye drops of the embodiment of the present invention is better than oral administration.
[0040] In summary, the embodiments of the present invention provide an eye drop containing a luteolin derivative and a preparation method thereof, wherein the luteolin derivative LTD2 is prepared in the form of eye drops to avoid the adverse effects of long-term enteral administration. Since LTD2 is more water-soluble than LTD, it has obvious advantages in being prepared into a preparation. However, due to its high water solubility, LTD2 is not easy to enter the eye through the cornea and sclera composed of lipid bilayer cell structures. Loading it on liposomes not only improves the stability of the drug molecules, but also facilitates the drug to penetrate directly into the retina, which can effectively prevent and alleviate the early stage of diabetic retinopathy. In addition, the preparation method of the eye drops is simple and has the potential to achieve large-scale industrial production.
[0041] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. An eye drop comprising a luteolin derivative, characterized in that: The eye drops include liposomes, and luteolin derivatives loaded on the liposomes; Wherein, the structural formula of the luteolin derivative is 。 2. The eye drops according to claim 1, characterized in that In the eye drops, the concentration of the luteolin derivative is 0.01wt%~0.05wt%.
3. The eye drops according to claim 1, characterized in that The drug loading amount of the liposome is 10wt%~30wt%.
4. The eye drops according to claim 1, characterized in that The particle size of the liposome is 100-400 nm.
5. The eye drops according to claim 1, characterized in that The liposome is a neutral liposome.
6. A method for preparing the eye drops containing luteolin derivatives according to any one of claims 1 to 5, characterized in that: include: dissolving lecithin and cholesterol in an organic solvent to obtain an organic phase solution; The organic phase solution is evaporated to remove the solvent to obtain a lipid film; mixing the lipid film with an aqueous solution containing the luteolin derivative to obtain a suspension; The suspension is diluted with a sodium chloride solution and its osmotic pressure is adjusted to obtain the eye drops.
7. The preparation method according to claim 6, characterized in that: The osmotic pressure of the eye drops is 280-300 mOsmol / kg.
8. The preparation method according to claim 6, characterized in that: The lipid film and the aqueous solution are mixed by stirring under ultrasonic conditions, with an ultrasonic frequency of 20 to 50 Hz, an ultrasonic time of 15 to 30 min, and a stirring speed of 500 to 1000 rpm.
Citation Information
Patent Citations
Bromfenac sodium lipidosome eye drop
CN103860467A
Preparation method of 6'-amino derivatives based on luteolin structure and application thereof
CN106674179A
A class of 3'-aminoalkoxy-luteolin derivatives, preparation method and applications thereof
CN110511201A
